期刊文献+

阿尔茨海默病及血管性痴呆患者血清胆固醇、Vit B_(12)和叶酸变化的临床研究☆ 被引量:10

A clinical study of Alzheimer's disease and vascular dementia in serum cholesterol, Vit B_(12), and folate acid
下载PDF
导出
摘要 目的探讨阿尔茨海默病(AD)和血管性痴呆(VaD)与血清胆固醇、血脂、VitB12和叶酸的关系。方法对35例AD、35例VaD和16例健康对照组血清胆固醇、血脂、叶酸及VitB12进行测定,并进行组间对比研究。结果AD组和VaD组血清胆固醇、甘油三酯明显高于对照组(P<0.05),并且VaD组甘油三酯水平与对照组相比差异更明显(P<0.01),而AD和VaD之间无显著性差异(P>0.05),VaD组叶酸水平显著低于AD组和正常对照组(P<0.05)。VitB12水平各组间相比无显著性差异(P>0.05)。结论血清叶酸水平降低可能与VaD发病有关,AD和VaD血清总胆固醇和甘油三酯明显增高,降低胆固醇及血脂可能对AD和VaD预防和治疗有益。 Objective To investigate the change of serum cholesterol, lipid, Vit B_ 12and folate acid in Alzheimer's disease (AD) and vascular dementia (VaD). Methods To measure serum concentrations of cholesterol, lipid,Vit B_ 12and folate acid in 35 patients with AD, 35 VaD and 16 normal controls respectively, and results were compared between each two groups by using Student test. Results The levels of serum cholesterol and triglyceride in AD and VaD were higher than those of normal control group, and there was significantly difference(P<0.05), and the levels of triglyceride in VaD group had strikingly different compared to control group (P<0.01), but there was no distinct difference between AD and VaD (P>0.05); The levels of serum folate acid in VaD group were lower than those in AD and normal control group, and there was distinct difference (P<0.05);The levels of serum Vit B_ 12had no significant difference between each group (P>0.05). Conclusions Decreased serum folate acid was probably associated with deterioration in VaD. The high levels of serum total cholesterol and triglyceride may be associated with AD and VaD. These results suggest that decreased cholesterol and triglyceride may provide potiential benefits in preventing and treating AD and VaD.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2005年第3期188-191,共4页 Chinese Journal of Nervous and Mental Diseases
基金 国家自然科学基金资助项目(编号:39370246) "九五"国家医学科技攻关项目(编号:969060507)
关键词 阿尔茨海默氏病 血管性痴呆 胆固醇 叶酸 VIT B12 Alzheimer's disease Vascular dementia Cholesterol folate acid Vitamin B_12
  • 相关文献

参考文献16

  • 1Jick H, Zomberg GL, Jick SS, et al. Statins and the risk of dementia.Lancet, 2000, 356(9242): 1627.
  • 2Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild congnitive impairment: a population-based study.Neurology, 2001, 56(12): 1683.
  • 3钱采韻.阿尔茨海默病的血管因素研究[J].中国神经精神疾病杂志,2002,28(6):475-476. 被引量:10
  • 4Whyte E, Mulsant BH, Butters MA, et al. Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. AmJ Geriatr Psychiatry, 2002, 10(3): 321.
  • 5Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. Int J Geriatr Psychiatry, 2000,15(3): 226.
  • 6Leblhuber F, Walli J, Artner-Dworzak E, et al. Hyperhomocysteinemia in dementia. J Neural Transm, 2000, 107(12):1469.
  • 7Cutler RG, Kelly J, Storie, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA, 2004, 101(7): 2070.
  • 8Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces-β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis, 2001, 8(5): 890.
  • 9Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocanpal neurons. Proc Natl Acad Sci USA, 1998,95(11): 6460.
  • 10Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.Neurobiol Dis, 2000, 7(4): 321.

二级参考文献15

  • 1[1]Shi J, Perry G, Smith MA, et al. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiology of Aging, 2000, 21 (2) :375.
  • 2[2]Kudo T, Imaizumi K, Tanimukai H, et al. Are cerebrovascular factor involved in Alzheimer's disease? Neurobiology of aging, 2000,21 (2): 215.
  • 3[3]M.M.B Breteler. Vascular risk factors for Alzheimers disease: An epidemiology perspective. Neurobiology of Aging, 2000,21 (2): 153.
  • 4[4]Launer L J, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD. Neurology, 2001,57(8): 1147.
  • 5[5]Shalden MF, Larson EB, Yukawa M. The epidemiology of Alzheimer's disease and vascular dementia in Japanese and Africian-Americian populations: the search for etiological clues. Neurobiology of Aging, 2000,21(2):171.
  • 6[6]Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiology of Aging, 2000,21(2) :321.
  • 7[7]Meyer JS, Rauch G, Rauch RA, et al. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiology of Aging,2000,21(2): 161.
  • 8[8]Hirono N, Kitagaki H, Kazui H, et al. Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study.Stroke, 2000,31(9) :2182.
  • 9[9]Johonson KA, Albert MS. Perfudion abnormalities in prodromal AD. Neurobiology of Aging, 2000,21(2) :289.
  • 10[10]Ni J, Ohta H, Matsumoto K, et al. Progressive congnitive impairmentfollowing chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Research, 1994,653( 1 -2):231.

共引文献9

同被引文献77

引证文献10

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部